مجله اخلاق پزشکی - علمی پژوهشی

El-Said MK. TRIPS-Plus, Public Health and Performance-Based Rewards Schemes: Options and Supplements for Policy Formation in Developing and Least Developed Countries. American University International Law Review. 2016;31(3):373-444.

Jafarzade M, Asadlou M. TRIPs-Plus Treaties and Strengthening Protection of Pharmaceutical Inventions. Medical Law Journal. 2020;14(53):233-57 .[Persian].

Sadeghi M. The Protection of Pharmaceutical Inventions and Human Rights Challenges. Law Quarterly. 2009;39(3):193-215.[Persian].

El-Said MK. The Road from TRIPS-Minus, to TRIPS, to TRIPS Plus: Implications of IPRS for the Arab World. Journal of World Intellectual Property. 2005;8(1):53-65.

Australian Government Department of Foreign Affairs and Trade. Comprehensive and Progressive Agreement for Trans-Pacific Partnership [Internet]. Australia: Department of Foreign Affairs and Trade; 2018 [cited 2024 Feb 14]. Available from: https://dfat.gov.au/trade/agreements/in-force/cptpp/official-documents.

Armouti W, Nsour MFA. Data Exclusivity for Pharmaceuticals: Was It the Best Choice for Jordan under the US-Jordan Free Trade Agreement. Oregon Review of International Law. 2016;17(2):259-306.

Armouti W. Evolution of Data exclusivity for pharmaceuticals in free trade agreements. Policy Brief. 2020;76:1-8.

Gleeson D, Lexchin J, Lopert R, Kilic B. The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries. Global Social Policy. 2017;18(1):7-27.

World Trade Organization. Agreement on Trade-Related Aspects of Intellectual Property Rights [Internet]. Geneva: World Trade Organization; 1994 [cited 2024 Feb 10]. Available from: https://www.wto.org/english/docs_e/legal_e/27-trips_01_e.htm.

Kuanpoth J. Intellectual Property Harmonisation under the Trans-Pacific Partnership Agreement: Issues and Challenges. Bangkok Research Center; 2017. Chapter 5. [cited 2024 Feb 9]. Available from: https://www.ide.go.jp/library/English/Publish/Reports/Brc/pdf/15_05.pdf

Khor M. The Need to Avoid "TRIPS-Plus" Patent Clauses in Trade Agreements [Internet]. Geneva: South Centre; 2017 [cited 2024 Feb 9]. Available from: https://martinkhor.org/wp-content/uploads/2020/09/PB37_The-Need-to-Avoid-%E2%80%9CTRIPS-Plus%E2%80%9D-Patent-Clauses-in-Trade-Agreements_EN.pdf.

Branstetter L. TPP and the Conflict over Drugs: Incentives for Innovation versus Access to Medicines. In: Schott JJ, Cimino-Isaac C, editors. Assessing the trans-Pacific partnership. Washington: Peterson Institute for International Economics; 2016. p. 20-32.

Pugatch MP. The International Regulation of IPRS in a TRIPS and TRIPS―plus World. The Journal of World Investment & Trade. 2005;6(3):431-65.

Office of the United States Trade Representative. United States-Jordan Free Trade Agreement [Internet]. United States: USTR; 2001 [cited 2024 Feb 12]. Available from: https://ustr.gov/trade-agreements/free-trade-agreements/jordan-fta.

El-Said H, El-Said M. TRIPS‐Plus Implications for Access to Medicines in Developing Countries: Lessons from Jordan–United States Free Trade Agreement. The Journal of World Intellectual Property. 2007;10(6):438-75.

European Union. Council Regulation (EC). no 469/2009 [Internet]. Brussels: The European Parliament; 2009 [cited 2024 Feb 14]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32009R0469.

U.S. Food and Drug Administration. Drug Price Competition and Patent Term Restoration Act [Internet]. United States: FDA; 1984 [Cited Feb 14 2024]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters.

Office of the United States Trade Representative. United States-Singapore Free Trade Agreement [internet]. United States: USTR; 2003 [cited 2024 Feb 12]. Available from: https://ustr.gov/trade-agreements/free-trade-agreements/singapore-fta.

Office of the United States Trade Representative. United States-Australia Free Trade Agreement [internet]. United States: USTR; 2004 [cited 2024 Feb 12]. Available from: https://ustr.gov/trade-agreements/free-trade-agreements/australia-fta.

Sadeghi M. Legal and Economic Challenges of Pharmaceutical New Use Patent for Developing Countries. Law Quarterly. 2010;40(1):159-78 [persian].

Ducimetière C. Second medical use patents: Legal treatment and public health issues. Research Paper no. 101. [Internet]. Geneva: South Centre; 2019 [cited 2024 Feb 10]. Available from: https://www.everycrsreport.com/files/20040723_RS21464_7e3dd78c87167a036f2320d1f6233bb6bb1b5753.pdf

Office of the United States Trade Representative. United States-Morocco Free Trade Agreement [Internet]. United States: USTR; 2004 [cited 2024 Feb 12]. Available from: https://ustr.gov/trade-agreements/free-trade-agreements/morocco-fta.

Office of the United States Trade Representative. United States-Oman Free Trade Agreement [Internet]. United States: USTR; 2006 [cited 2024 Feb 12]. Available from: https://ustr.gov/trade-agreements/free-trade-agreements/oman-fta.

El-Said M. The morning after: TRIPS-Plus, FTAs, and Wikileaks: Fresh insights on the implementation and enforcement of IP protection in developing countries. American University International Law Review. 2012;1-30.

Office of the United States Trade Representative. United States-Mexico-Canada Agreement [Internet]. United States: USTR; 2020 [cited 2024 Feb 12]. Available from: https://ustr.gov/trade-agreements/free-trade-agreements/united-states-mexico-canada-agreement.